Bone metabolism and histomorphometric changes in murine models treated with sclerostin antibody: A systematic review

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Preventing osteoporotic fractures in millions of individuals may significantly reduce the associated morbidity and health-care expenditures incurred. As such, the search for newer anti-osteoporotic agents has been ongoing for years. Genetic studies have proven that the secreted protein sclerostin is one of the main culprits, which negatively regulates the bone formation. Recently, sclerostin-neutralizing monoclonal antibodies (Scl-Ab) in rodent studies have shown positive effects on bone homeostasis. An extensive search of the literature was performed in the BIOSIS, Cinahl, EMBASE, Pub-Med, Web of Science and Cochrane Library databases to evaluate the published murine studies on the effects of Scl-Ab on the bone metabolism and histomorphometric parameters. Our systematic review depicts a significant association between Scl-Ab administration and improvement in bone formation, bone density, bone volume and trabecular thickness.

Original languageEnglish
Pages (from-to)1667-1674
Number of pages8
JournalCurrent Drug Targets
Volume14
Issue number14
DOIs
Publication statusPublished - 2013

Fingerprint

Metabolism
Bone
Neutralizing Antibodies
Bone and Bones
Antibodies
Monoclonal Antibodies
Osteogenesis
Library Science
Osteoporotic Fractures
Health Expenditures
Bone Density
Rodentia
Homeostasis
Databases
Morbidity
Delivery of Health Care
Health care
Proteins

Keywords

  • Bone formation
  • Bone histomorphometry
  • Bone metabolism
  • Sclerostin antibody

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

@article{47fc6895e8e844359cfaee696b78f3d5,
title = "Bone metabolism and histomorphometric changes in murine models treated with sclerostin antibody: A systematic review",
abstract = "Preventing osteoporotic fractures in millions of individuals may significantly reduce the associated morbidity and health-care expenditures incurred. As such, the search for newer anti-osteoporotic agents has been ongoing for years. Genetic studies have proven that the secreted protein sclerostin is one of the main culprits, which negatively regulates the bone formation. Recently, sclerostin-neutralizing monoclonal antibodies (Scl-Ab) in rodent studies have shown positive effects on bone homeostasis. An extensive search of the literature was performed in the BIOSIS, Cinahl, EMBASE, Pub-Med, Web of Science and Cochrane Library databases to evaluate the published murine studies on the effects of Scl-Ab on the bone metabolism and histomorphometric parameters. Our systematic review depicts a significant association between Scl-Ab administration and improvement in bone formation, bone density, bone volume and trabecular thickness.",
keywords = "Bone formation, Bone histomorphometry, Bone metabolism, Sclerostin antibody",
author = "Srijit Das and Sakthiswary Rajalingham",
year = "2013",
doi = "10.2174/1389450114666131217001756",
language = "English",
volume = "14",
pages = "1667--1674",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "14",

}

TY - JOUR

T1 - Bone metabolism and histomorphometric changes in murine models treated with sclerostin antibody

T2 - A systematic review

AU - Das, Srijit

AU - Rajalingham, Sakthiswary

PY - 2013

Y1 - 2013

N2 - Preventing osteoporotic fractures in millions of individuals may significantly reduce the associated morbidity and health-care expenditures incurred. As such, the search for newer anti-osteoporotic agents has been ongoing for years. Genetic studies have proven that the secreted protein sclerostin is one of the main culprits, which negatively regulates the bone formation. Recently, sclerostin-neutralizing monoclonal antibodies (Scl-Ab) in rodent studies have shown positive effects on bone homeostasis. An extensive search of the literature was performed in the BIOSIS, Cinahl, EMBASE, Pub-Med, Web of Science and Cochrane Library databases to evaluate the published murine studies on the effects of Scl-Ab on the bone metabolism and histomorphometric parameters. Our systematic review depicts a significant association between Scl-Ab administration and improvement in bone formation, bone density, bone volume and trabecular thickness.

AB - Preventing osteoporotic fractures in millions of individuals may significantly reduce the associated morbidity and health-care expenditures incurred. As such, the search for newer anti-osteoporotic agents has been ongoing for years. Genetic studies have proven that the secreted protein sclerostin is one of the main culprits, which negatively regulates the bone formation. Recently, sclerostin-neutralizing monoclonal antibodies (Scl-Ab) in rodent studies have shown positive effects on bone homeostasis. An extensive search of the literature was performed in the BIOSIS, Cinahl, EMBASE, Pub-Med, Web of Science and Cochrane Library databases to evaluate the published murine studies on the effects of Scl-Ab on the bone metabolism and histomorphometric parameters. Our systematic review depicts a significant association between Scl-Ab administration and improvement in bone formation, bone density, bone volume and trabecular thickness.

KW - Bone formation

KW - Bone histomorphometry

KW - Bone metabolism

KW - Sclerostin antibody

UR - http://www.scopus.com/inward/record.url?scp=84891680530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891680530&partnerID=8YFLogxK

U2 - 10.2174/1389450114666131217001756

DO - 10.2174/1389450114666131217001756

M3 - Article

C2 - 24354585

AN - SCOPUS:84891680530

VL - 14

SP - 1667

EP - 1674

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 14

ER -